Cormorant Asset Management, LP - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 95 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2017. The put-call ratio across all filers is 28.57 and the average weighting 0.4%.

Quarter-by-quarter ownership
Cormorant Asset Management, LP ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2021$4,356,000
-61.2%
300,000
-45.5%
0.15%
-40.8%
Q1 2021$11,226,000
+14.9%
550,0000.0%0.25%
+7.3%
Q4 2020$9,773,000
+1.7%
550,000
-15.4%
0.23%
-37.0%
Q3 2020$9,611,000
+357.9%
650,072
+550.1%
0.37%
+362.5%
Q2 2020$2,099,000
-9.2%
100,0000.0%0.08%
-25.2%
Q1 2020$2,311,000
+78.5%
100,000
+100.0%
0.11%
+105.8%
Q4 2019$1,295,000
-94.3%
50,000
-94.3%
0.05%
-97.2%
Q4 2018$22,645,000
-37.0%
884,916
-19.6%
1.84%
-21.3%
Q3 2018$35,937,000
+21.9%
1,100,000
-15.4%
2.34%
+7.1%
Q2 2018$29,484,000
-6.5%
1,300,0000.0%2.18%
-7.1%
Q1 2018$31,525,000
+25.6%
1,300,000
+44.4%
2.35%
-10.6%
Q4 2017$25,101,000
-22.8%
900,000
-5.3%
2.63%
-54.2%
Q3 2017$32,528,000
-14.1%
950,0000.0%5.74%
-8.5%
Q2 2017$37,848,000
-27.9%
950,000
-33.3%
6.27%
-17.7%
Q1 2017$52,469,000
+15.5%
1,425,0000.0%7.62%
+24.4%
Q4 2016$45,429,000
+12.1%
1,425,000
+27.4%
6.12%
+37.0%
Q3 2016$40,530,000
+59.7%
1,118,3720.0%4.47%
+24.2%
Q2 2016$25,376,0001,118,3723.60%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2017
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,269,584$69,497,223,00012.98%
Newtyn Management, LLC 1,375,000$13,145,0003.15%
Chescapmanager LLC 1,166,574$11,152,0001.51%
Baupost Group 13,643,333$130,430,0001.40%
Weiss Asset Management LP 5,412,487$51,743,0001.07%
CM Management, LLC 120,000$1,147,0000.96%
Orbimed Advisors 3,254,713$31,115,0000.50%
King Wealth Management Group 122,000$1,166,0000.23%
Woodline Partners LP 1,326,653$12,683,0000.21%
PDT Partners, LLC 192,701$1,842,0000.16%
View complete list of THERAVANCE BIOPHARMA INC shareholders